These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 12096352

  • 1. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA.
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [Abstract] [Full Text] [Related]

  • 2. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A, Thiele J.
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [Abstract] [Full Text] [Related]

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Jan; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 6. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A, Elliott MA, Solberg LA, Silverstein MN.
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [Abstract] [Full Text] [Related]

  • 8. Modern treatment strategies in polycythemia vera.
    Gilbert HS.
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
    [Abstract] [Full Text] [Related]

  • 9. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 10. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 11. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [Abstract] [Full Text] [Related]

  • 12. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G, Barbui T.
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [Abstract] [Full Text] [Related]

  • 13. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 14. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D, Mascarenhas J.
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [Abstract] [Full Text] [Related]

  • 15. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS.
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [Abstract] [Full Text] [Related]

  • 16. Other secondary sequelae of treatments for myeloproliferative disorders.
    Gilbert HS.
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):22-7. PubMed ID: 12096354
    [Abstract] [Full Text] [Related]

  • 17. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C, Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas.
    Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
    Golub R, Adams J, Dave S, Bennett CL.
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):28-32. PubMed ID: 12096355
    [Abstract] [Full Text] [Related]

  • 19. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A, Silverstein MN.
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [Abstract] [Full Text] [Related]

  • 20. [Essential thrombocythemia: conventional therapy].
    Grossi A, Vannucchi AM, Longo G, Rafanelli D, Rossi Ferrini P.
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.